Oppenheimer Initiates Coverage on Curis with an Outperform Rating

According to Oppenheimer, Curis

coverage is initiated with an Outperform rating. Oppenheimer said that it is initiating coverage of Curis Inc. with an Outperform rating and $6/share price target. “Our target price of $6/share is based on an NPV analysis of vismodegib in BCC and Gorlin syndrome, and we believe that a considerable upside remains outside of these indications and in the remainder of Curis's pipeline.” Curis closed yesterday at $3.56.